Novartis US Medical’s Post

🔍 Recent research by Kanishka Agarwal and colleagues points to critical gaps in #LewyBodyDementia. By mapping the landscape, they focus on advocacy, funding, research, and patient impact. Their prescription? Standardised tools, accurate diagnoses, and biomarkers 🧠 #LBDResearch #Innovation https://lnkd.in/ews49EdK

Diversity in clinical trial participation is extremely important for efficacy and safety of medical treatments across the whole population, as well as for health equity and ethics. While some progress has been made, such as U.S. Food and Drug Administration Omnibus Reform Act of 2022 (FDORA), participation statistics show clinical trial participant populations aren't reflective of the actual U.S. population. One of the main barriers continues to be clinical trial accessibility. One possible strategy for diverse, inclusive clinical research is optimized trial design. This is defined as "virtual clinical trials designed to create ideal conditions for both patients and sponsors." Learn more about this design and how it can reduce barriers for diverse clinical trial participation in ACRP's Clinical Researcher journal: https://lnkd.in/gzJAN2PY #clinicaltrials #cancer #cancerresearch #clinicalresearch #research #healthcare #healthequity #health #wellness #oncology

We are all individuals, and our responsiveness to interventions can differ significantly based on our unique characteristics. This is why medical trials must consider genetic, biological, and socio-economic differences between people. Read a blog article by Orion’s Catherine Akello-Opio, Assistant Director, Pain Therapy Area USA, on the importance of diversity and equity in patients participating in clinical trials 👇 #ClinicalTrials #Diversity #Equity #Orion 

Yesterday marked #RareDiseases Day, prompting reflection on the valuable insights shared in this article from last year. It underscores the profound impact of digital and analytics capabilities in transforming the diagnosis, treatment, and support of rare disease patients. Technology not only enhances patient care and experience by facilitating improved identification and remote monitoring but also enables personalized treatment plans. Despite notable advancements, challenges persist in diagnosing patients, addressing treatment burdens, and scaling therapies. Nevertheless, collaborative efforts among pharmaceutical companies, patient advocacy groups, and healthcare providers are instrumental in overcoming these hurdles and ultimately enhancing the lives of individuals with rare diseases. Thanks to the authors for this amazing piece: Simon Alfano Christian Amberg Nils Peters Pablo Salazar Marianne Renaud Vieux-Rochas Sam Welton Jeffrey Algazy Jan Ascher Anton Maucuer #RareDiseasesDay #DigitalHealth #PatientsFirst

📃Scientific paper: Statin Use and Incidence of Parkinson's Disease in Women from the French E3N Cohort Study Abstract: International audience; Background: Statins represent candidates for drug repurposing in Parkinson's disease (PD). Few studies examined the role of reverse causation, statin subgroups, and dose–response relations based on time-varying exposures. Objectives: We examined whether statin use is associated with PD incidence while attempting to overcome the limitations described previously, especially reverse causation. Method: We used data from the E3N cohort study of French women (follow-up, 2004–2018). Incident PD was ascertained using multiple sources and validated by experts. New statin users were identified through linked drug claims. We set up a nested case-control study to describe trajectories of statin prescriptions and medical consultations before diagnosis. We used time-varying multivariable Cox proportional hazards regression models to examine the statins–PD association. Exposure indexes included ever use, cumulative duration/dose, and mean daily dose and were lagged by 5 years to address reverse causation. Results: The case-control study (693 cases, 13,784 controls) showed differences in case-control trajectories, with changes in the 5 years before diagnosis in cases. Of 73,925 women (aged 54–79 years), 524 developed PD and 11,552 started using statins in lagged analyses. Ever use of any statin was not associated with PD (hazard ratio [HR] = 0.87, 95% confidence interval [CI] = 0.67–1.11). Alternatively, ever use of lipophilic statins was s... Continued on ES/IODE ➡️ https://etcse.fr/IakKM ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Statin Use and Incidence of Parkinson's Disease in Women from the French E3N Cohort Study Abstract: International audience; Background: Statins represent candidates for drug repurposing in Parkinson's disease (PD). Few studies examined the role of reverse causation, statin subgroups, and dose–response relations based on time-varying exposures. Objectives: We examined whether statin use is associated with PD incidence while attempting to overcome the limitations described previously, especially reverse causation. Method: We used data from the E3N cohort study of French women (follow-up, 2004–2018). Incident PD was ascertained using multiple sources and validated by experts. New statin users were identified through linked drug claims. We set up a nested case-control study to describe trajectories of statin prescriptions and medical consultations before diagnosis. We used time-varying multivariable Cox proportional hazards regression models to examine the statins–PD association. Exposure indexes included ever use, cumulative duration/dose, and mean daily dose and were lagged by 5 years to address reverse causation. Results: The case-control study (693 cases, 13,784 controls) showed differences in case-control trajectories, with changes in the 5 years before diagnosis in cases. Of 73,925 women (aged 54–79 years), 524 developed PD and 11,552 started using statins in lagged analyses. Ever use of any statin was not associated with PD (hazard ratio [HR] = 0.87, 95% confidence interval [CI] = 0.67–1.11). Alternatively, ever use of lipophilic statins was s... Continued on ES/IODE ➡️ https://etcse.fr/IakKM ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Statin Use and Incidence of Parkinson's Disease in Women from the French E3N Cohort Study Abstract: International audience; Background: Statins represent candidates for drug repurposing in Parkinson's disease (PD). Few studies examined the role of reverse causation, statin subgroups, and dose–response relations based on time-varying exposures. Objectives: We examined whether statin use is associated with PD incidence while attempting to overcome the limitations described previously, especially reverse causation. Method: We used data from the E3N cohort study of French women (follow-up, 2004–2018). Incident PD was ascertained using multiple sources and validated by experts. New statin users were identified through linked drug claims. We set up a nested case-control study to describe trajectories of statin prescriptions and medical consultations before diagnosis. We used time-varying multivariable Cox proportional hazards regression models to examine the statins–PD association. Exposure indexes included ever use, cumulative duration/dose, and mean daily dose and were lagged by 5 years to address reverse causation. Results: The case-control study (693 cases, 13,784 controls) showed differences in case-control trajectories, with changes in the 5 years before diagnosis in cases. Of 73,925 women (aged 54–79 years), 524 developed PD and 11,552 started using statins in lagged analyses. Ever use of any statin was not associated with PD (hazard ratio [HR] = 0.87, 95% confidence interval [CI] = 0.67–1.11). Alternatively, ever use of lipophilic statins was s... Continued on ES/IODE ➡️ https://etcse.fr/IakKM ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Statin Use and Incidence of Parkinson's Disease in Women from the French E3N Cohort Study Abstract: International audience; Background: Statins represent candidates for drug repurposing in Parkinson's disease (PD). Few studies examined the role of reverse causation, statin subgroups, and dose–response relations based on time-varying exposures. Objectives: We examined whether statin use is associated with PD incidence while attempting to overcome the limitations described previously, especially reverse causation. Method: We used data from the E3N cohort study of French women (follow-up, 2004–2018). Incident PD was ascertained using multiple sources and validated by experts. New statin users were identified through linked drug claims. We set up a nested case-control study to describe trajectories of statin prescriptions and medical consultations before diagnosis. We used time-varying multivariable Cox proportional hazards regression models to examine the statins–PD association. Exposure indexes included ever use, cumulative duration/dose, and mean daily dose and were lagged by 5 years to address reverse causation. Results: The case-control study (693 cases, 13,784 controls) showed differences in case-control trajectories, with changes in the 5 years before diagnosis in cases. Of 73,925 women (aged 54–79 years), 524 developed PD and 11,552 started using statins in lagged analyses. Ever use of any statin was not associated with PD (hazard ratio [HR] = 0.87, 95% confidence interval [CI] = 0.67–1.11). Alternatively, ever use of lipophilic statins was s... Continued on ES/IODE ➡️ https://etcse.fr/IakKM ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Statin Use and Incidence of Parkinson's Disease in Women from the French E3N Cohort Study Abstract: International audience; Background: Statins represent candidates for drug repurposing in Parkinson's disease (PD). Few studies examined the role of reverse causation, statin subgroups, and dose–response relations based on time-varying exposures. Objectives: We examined whether statin use is associated with PD incidence while attempting to overcome the limitations described previously, especially reverse causation. Method: We used data from the E3N cohort study of French women (follow-up, 2004–2018). Incident PD was ascertained using multiple sources and validated by experts. New statin users were identified through linked drug claims. We set up a nested case-control study to describe trajectories of statin prescriptions and medical consultations before diagnosis. We used time-varying multivariable Cox proportional hazards regression models to examine the statins–PD association. Exposure indexes included ever use, cumulative duration/dose, and mean daily dose and were lagged by 5 years to address reverse causation. Results: The case-control study (693 cases, 13,784 controls) showed differences in case-control trajectories, with changes in the 5 years before diagnosis in cases. Of 73,925 women (aged 54–79 years), 524 developed PD and 11,552 started using statins in lagged analyses. Ever use of any statin was not associated with PD (hazard ratio [HR] = 0.87, 95% confidence interval [CI] = 0.67–1.11). Alternatively, ever use of lipophilic statins was s... Continued on ES/IODE ➡️ https://etcse.fr/IakKM ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

I recently saw a thought-provoking article about diversity being underrepresented in clinical trials: "Does underrepresentation affect results? One may wonder whether the failure to balance the pool of diabetes research participants twists the results. The short answer is that in general, it likely does not. While there is a genetic component to diabetes, we know from other research that physiologically speaking, people are more often similar in terms of responding to disease and to treatments, so the drugs we prescribe are legitimately effective. However, detecting ethnic differences in serious adverse reactions to experimental drugs is more difficult because they are less frequent. Some may occur more frequently in ethnically diverse groups due to differences in the frequency of genetic variants or physiologic responses, leaving some vulnerable to hidden problems that a more diversified clinical trial participant pool could have exposed." You can check out the whole article here: https://lnkd.in/enHFfneT What's your take-away?